CLABF - Core One Labs' initiates development of AKO001 for neurological damage files provisional patent

Core One Labs' (CLABF) wholly owned subsidiary Akome Biotech has commenced the development of a next-generation psychedelic drug formulation for the purpose of mitigating neurological damage that results from ischemic strokes. Akome’s psychedelic drug formulation, also known as AKO001, is comprised of the psychedelic compound N,N-dimethyltryptamine ((DMT)) and a specific plant bioactive.A provisional matter of composition patent application for AKO001 has been filed with the USPTO under application 63147343. The bioactive shows evidence of promoting positive apoptotic processes, and the DMT induces the formation of glial cells. These complimentary functions could theoretically optimize in vivo replacement of neurons after neural injury, such as a stroke.Akome is in process of identifying Contract Research Organizations to work with as it sets the development process of AKO001 psychedelic drug formulation and its advancement for the treatment of stroke.

For further details see:

Core One Labs' initiates development of AKO001 for neurological damage, files provisional patent